These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7097455)

  • 1. Particulate inspection of parenteral products: from biophysics to automation.
    Knapp JZ; Kushner HK
    J Parenter Sci Technol; 1982; 36(3):121-7. PubMed ID: 7097455
    [No Abstract]   [Full Text] [Related]  

  • 2. Particulate inspection of parenteral products: an assessment.
    Knapp JZ; Kushner HK; Abramson LR
    J Parenter Sci Technol; 1981; 35(4):176-85. PubMed ID: 7277132
    [No Abstract]   [Full Text] [Related]  

  • 3. Standards for particulate matter in all parenteral drug products.
    Jeffrey LP; Pinkus TF
    Am J Hosp Pharm; 1976 Sep; 33(9):879-80. PubMed ID: 984053
    [No Abstract]   [Full Text] [Related]  

  • 4. Particulate Generation Mechanisms during Bulk Filling and Mitigation via New Glass Vial.
    Timmons CL; Liu CY; Merkle S
    PDA J Pharm Sci Technol; 2017; 71(5):379-392. PubMed ID: 28512178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Particulate matter standards for small-volume injections.
    Belson JJ
    Am J Hosp Pharm; 1986 Jun; 43(6):1527-8. PubMed ID: 3728492
    [No Abstract]   [Full Text] [Related]  

  • 6. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirtieth report.
    World Health Organ Tech Rep Ser; 1987; 748():1-50. PubMed ID: 3111103
    [No Abstract]   [Full Text] [Related]  

  • 7. [Possibilities of material contamination due to additional injections].
    Müller-Stock A
    Klin Anasthesiol Intensivther; 1977; (14):114-20. PubMed ID: 926677
    [No Abstract]   [Full Text] [Related]  

  • 8. [Possibilities of material contamination due to additional injections].
    Mehrkens HH; Klaus E; Schmitz JE
    Klin Anasthesiol Intensivther; 1977; (14):106-13. PubMed ID: 926676
    [No Abstract]   [Full Text] [Related]  

  • 9. Industry perspective on the medical risk of visible particles in injectable drug products.
    Bukofzer S; Ayres J; Chavez A; Devera M; Miller J; Ross D; Shabushnig J; Vargo S; Watson H; Watson R
    PDA J Pharm Sci Technol; 2015; 69(1):123-39. PubMed ID: 25691720
    [No Abstract]   [Full Text] [Related]  

  • 10. Influence of compounding on sterility and stability of drugs.
    Hardee GE
    J Am Vet Med Assoc; 1994 Jul; 205(2):224-5. PubMed ID: 7928582
    [No Abstract]   [Full Text] [Related]  

  • 11. USP general chapter <797> pharmaceutical compounding-sterile preparations.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
    [No Abstract]   [Full Text] [Related]  

  • 12. [Validation of sterile pharmaceutical production. Considerations and experiences].
    Pongiluppi S
    Boll Chim Farm; 1985 Jul; 124(7):293-305. PubMed ID: 4074520
    [No Abstract]   [Full Text] [Related]  

  • 13. [For a strict quality of active pharmaceutical ingredients].
    Astier A
    Ann Pharm Fr; 2008 Mar; 66(2):69-70. PubMed ID: 18570901
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of methods for detection of particulate matter in large-volume perenterals.
    Blanchard J; Thompson CM; Schwartz JA
    Am J Hosp Pharm; 1976 Feb; 33(2):144-50. PubMed ID: 1258874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adulteration of drugs and foods: compendial approaches to lowering risk.
    Abernethy DR; Sheehan C; Griffiths JC; Williams RL;
    Clin Pharmacol Ther; 2009 Apr; 85(4):444-7. PubMed ID: 18463621
    [No Abstract]   [Full Text] [Related]  

  • 16. PDA particulate matter panel discussion--an industry perspective.
    Hammer HF
    J Parenter Sci Technol; 1984; 38(5):170-2. PubMed ID: 6512655
    [No Abstract]   [Full Text] [Related]  

  • 17. Particulate matter in parenteral products: a review.
    Borchert SJ; Abe A; Aldrich DS; Fox LE; Freeman JE; White RD
    J Parenter Sci Technol; 1986; 40(5):212-41. PubMed ID: 3540253
    [No Abstract]   [Full Text] [Related]  

  • 18. Protecting consumers from counterfeit drugs.
    FDA Consum; 2004; 38(3):12-3. PubMed ID: 15218838
    [No Abstract]   [Full Text] [Related]  

  • 19. Anticipated revisions to the current good manufacturing practice regulations.
    Mitchell CM
    Bull Parenter Drug Assoc; 1974; 28(3):146-51. PubMed ID: 4845938
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter: Particulate contamination--let's solve the problem.
    Bailey DE
    Am J Hosp Pharm; 1974 Jan; 31(1):30. PubMed ID: 4810163
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.